View a markdown version of this page

Sustainability - Life Sciences Lens

Sustainability

Sustainability reporting is increasingly recognized as both important and strategically beneficial for life sciences companies. While it's not yet a global legal mandate, the trend is moving toward mandatory Environmental, Social, and Governance (ESG) and sustainability disclosure, with voluntary reporting already strongly encouraged by investors and customers.

In the European Union, sustainability reporting has become mandatory for many life sciences companies under the Corporate Sustainability Reporting Directive (CSRD)

The CSRD requires in-scope companies, including large life sciences and biotech firms, to prepare detailed sustainability reports covering:

  • Environmental impact (including climate change, resource use, pollution, and biodiversity)

  • Social factors (employee rights, diversity, and community engagement)

  • Governance (business ethics and risk management)

  • Supply chain transparency

  • Double materiality (both the impact of sustainability matters on the company and the company's impact on society and the environment)

Companies must report in accordance with the European Sustainability Reporting Standards (ESRS), and the requirements are being phased in, with additional sector-specific standards expected by 2026. ​ The sustainability pillar focuses on minimizing the environmental impact of running life sciences workloads in the cloud while, at the same time, meeting critical regulatory requirements, data integrity and retention needs as well as the specific scientific computing demands.

Life sciences organizations face unique sustainability challenges due to industry specifics such as:

  • Compute-intensive processes for research, genomic analysis, and molecular modeling

  • Long-term data retention requirements for regulatory adherence

  • High-performance computing needs for drug discovery and clinical analysis

  • Large-scale data collection and processing from laboratory instruments

  • Global collaboration requirements across research sites and clinical trials